{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:Q06529",
      "entity_text" : "Fc",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ03972",
      "entity_text" : "pembrolizumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Previous studies in mice have shown that anti-CTLA-4 monoclonal antibodies including ipilimumab, pembrolizumab, and tremelimumab, block the function of CTLA-4 and deplete intratumoral FOXP3 + regulatory T cells via an Fc dependent mechanism XREF_BIBR - XREF_BIBR.",
  "reading_complete" : "2020-08-03T13:52:23Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T13:50:32Z",
  "trigger" : "deplete",
  "evidence" : [ "pembrolizumab, and tremelimumab, block the function of CTLA-4 and deplete intratumoral FOXP3 +  regulatory T cells via an Fc" ],
  "pmc_id" : "6531311",
  "score" : 0
}